AHR antagonist expanded hematopoietic stem cell therapy (Magenta Therapeutics)

N/A

Report date: 2025/01/26 17:08:30

Base Information

Drug NameAHR antagonist expanded hematopoietic stem cell therapy (Magenta Therapeutics)

Drug Alias NameAHR antagonist expanded HSC cell therapy (Magenta Therapeutics)ex-vivo expanded peripheral blood/bone marrow-derived hematopoietic stem cell therapy (Magenta Therapeutics)aryl hydrocarbon receptor antagonist-expanded HSC cells (Magenta Therapeutics)E-478

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionHaematopoiesis stimulantsStem cells stimulantsImmunomodulators

TargetsUpdating

Therapy Area/IndicationsThalassemiaAnemia, Sickle CellHematopoietic stem cell transplantation (HSCT)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMagenta Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesMagenta Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsThalassemiaAnemia, Sickle CellHematopoietic stem cell transplantation (HSCT)

Inactive IndicationsN/A

Other Information

ATC CodeN/A